These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9315413)

  • 1. The effects of oral contraceptives on delayed onset muscle soreness following exercise.
    Thompson HS; Hyatt JP; De Souza MJ; Clarkson PM
    Contraception; 1997 Aug; 56(2):59-65. PubMed ID: 9315413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral contraceptive use on female sexual salivary hormones and indirect markers of muscle damage following eccentric cycling in women.
    Mackay K; González C; Zbinden-Foncea H; Peñailillo L
    Eur J Appl Physiol; 2019 Dec; 119(11-12):2733-2744. PubMed ID: 31686212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-sparing properties of oral contraceptives.
    DeCherney A
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):15-20. PubMed ID: 8571999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blunted Myoglobin and Quadriceps Soreness After Electrical Stimulation During the Luteal Phase or Oral Contraception.
    Anderson LJ; Baker LL; Schroeder ET
    Res Q Exerc Sport; 2017 Jun; 88(2):193-202. PubMed ID: 28388333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of the Oral Contraceptive Cycle Phase on Exercise-Induced Muscle Damage After Eccentric Exercise in Resistance-Trained Women.
    Romero-Parra N; Rael B; Alfaro-Magallanes VM; Janse de Jonge X; Cupeiro R; Peinado AB;
    J Strength Cond Res; 2021 Feb; 35(2):353-359. PubMed ID: 33337689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
    Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
    Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low dose oral contraceptives on exercise performance.
    Bryner RW; Toffle RC; Ullrich IH; Yeater RA
    Br J Sports Med; 1996 Mar; 30(1):36-40. PubMed ID: 8665116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of combined oral contraceptive preparations.
    Singh BM; Nutter SA; Nattrass M
    Contraception; 1987 Dec; 36(6):651-8. PubMed ID: 3128428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives. Who, which, when, and why?
    Marut EL
    Postgrad Med; 1987 Sep; 82(4):66-70. PubMed ID: 3628138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of estrogen on markers of muscle tissue damage following eccentric exercise.
    Carter A; Dobridge J; Hackney AC
    Fiziol Cheloveka; 2001; 27(5):133-7. PubMed ID: 11680291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptive use and exercise-induced muscle damage and recovery.
    Savage KJ; Clarkson PM
    Contraception; 2002 Jul; 66(1):67-71. PubMed ID: 12169383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
    Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
    J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
    Jespersen J
    Gynecol Obstet Invest; 1983; 15(5):266-74. PubMed ID: 6852646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of relaxin during the menstrual cycle and oral contraceptive use.
    Wreje U; Kristiansson P; Aberg H; Byström B; von Schoultz B
    Gynecol Obstet Invest; 1995; 39(3):197-200. PubMed ID: 7789917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of recurrent menstrual psychosis by an oral contraceptive.
    Felthous AR; Robinson DB; Conroy RW
    Am J Psychiatry; 1980 Feb; 137(2):245-6. PubMed ID: 6101529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of oral contraceptives.
    Sherif K
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S343-8. PubMed ID: 10368519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.